Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-CD133 bispecific CAR-iNKT
- Development stage
- Preclinical
- Lead developer
- Imperial College London
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
CD19-CD133 bispecific CAR-iNKT is a preclinical, allogeneic, off-the-shelf cell therapy utilizing invariant natural killer T (iNKT) cells. These cells are engineered to co-express two chimeric antigen receptors (CARs): a second-generation CD19-28ζ CAR and a CD133-4-1BBζ CAR. This dual-targeting approach is designed to enhance antileukemic activity and prevent immune escape in KMT2A-rearranged acute lymphoblastic leukemia (KMT2Ar-ALL), a high-risk subtype common in infants. iNKT cells are used as the platform because they do not cause graft-versus-host disease (GVHD) and possess inherent trafficking advantages, such as VLA-4-mediated adhesion, which facilitates entry into the central nervous system to treat leptomeningeal disease. The therapy's mechanism of action involves both CAR-mediated cytotoxicity and NKG2D-dependent killing.
- Other names
- CD19/CD133 CAR-iNKT
02
Targets
CD133 (CD133 antigen)CD19 (B lymphocyte antigen CD19)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on CD19-CD133 bispecific CAR-iNKT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-CD133 bispecific CAR-iNKT.